US stock · figures in US dollars · scored on full-year results
Bristol Myers Squibb Bristol-Myers Squibb Company Common Stock
Bristol Myers Squibb scores 55/100 on fundamentals: in the top 46% of 503 scored S&P 500 stocks. Its strongest area is Risk (75/100); its weakest is Price Fairness (17/100). It carries 3 warning flags: Weak Spot, Profit Spike, Recent Loss.
- Carries a Weak Spot flag
- Carries a Profit Spike flag
- Carries a Recent Loss flag
This stock is fairly balanced overall: price fairness is its weakest area.
Nearby peers
Ranks #26 of 60 in Healthcare by score
One-Minute Summary
Why Bristol Myers Squibb scores 55
This stock is fairly balanced overall: price fairness is its weakest area.
Business Strength
50Why 50?
Show 3 charts
Net Profit & Equity, with ROE
Revenue & Net Profit, with Net Margin
Sales grew about 11.2% over 4 years: customers keep spending more with this company.
The company lost money in recent years: the bars below zero are losses, not profits.
Recent Quarters: Revenue & Net Profit (the last 8 quarters, scored)
Sales grew about 9.1% over the last 8 quarters: customers keep spending more with this company.
Profit grew about 173.9% over the last 8 quarters: the business is keeping more of what it earns.
Financial Safety
67Why 67?
Show 2 charts
Debt vs Equity, with D/E ratio
Borrowings have stayed roughly level: manageable, as long as profits stay healthy.
Short-term assets vs bills, with Current Ratio
Cash & Dividends
63Why 63?
Show 3 charts
Operating vs Free Cash Flow
Cash keeps coming in, though unevenly: fine, but worth keeping an eye on.
Cash vs Total Debt
Dividends per Share, with Yield
Dividends per share have been maintained or raised: management shares the rewards with you.
Price FairnessLowest pillar
17Why 17?
Show chart
Share Price: Weekly Closes (not part of the score)
The share price is up about 41.7% over the past year.
Risk
75Why 75?
Show chart
Revenue vs Inventory, with Inventory % of Revenue
Sector peers
Bristol Myers Squibb (BMY) scores 55/100 (Okay) on Score Your Stock's educational fundamentals model: in the top 46% of 503 scored S&P 500 stocks.
Its strongest pillar is Risk (75/100); its weakest is Price Fairness (17/100).
Bristol Myers Squibb ranks #26 of 60 scored Healthcare stocks on Score Your Stock.
Yes. Bristol Myers Squibb (BMY) has a dividend yield of 4%, from dividends with an ex-date in the last 12 months. It pays out 55% of its profit as dividends. Its Cash & Dividends pillar scores 63/100.
From Malaysia, open an account with a broker that offers US shares (many local and app-based brokers do), convert ringgit to US dollars, then buy BMY. US shares trade one share at a time, not in lots of 100. Check the currency conversion fee and US dividend tax (usually 30% withheld for Malaysians) before you buy.
The overall score pools every measure across 5 weighted pillars: Business Strength, Financial Safety, Cash & Dividends, Price Fairness, and Risk. It uses the same rules as our Bursa scores. For banks, Financial Safety checks nonaccrual (impaired) loans, loan loss coverage and the CET1 capital ratio, from the FDIC call report of the group's main bank. Full methodology and the default weights: https://scoreyourstock.com/how. This is an educational tool, not investment advice.
Bristol Myers Squibb (BMY) is a Healthcare company (Drug Manufacturers - General). On Score Your Stock's fundamentals check, it scores 55/100, rated Okay. Its biggest strength is Risk (75/100); its main watch-out is Price Fairness (17/100). Shares currently cost about 14 years of its current profit to buy (P/E 13.8×). It also pays back about 4.0% of the share price as dividends each year. Full breakdown and daily-updated score: https://scoreyourstock.com/stocks/us/bmy-bristol-myers-squibb
Full Financial History
Every reported figure behind the score, year by year. Download it, or check it against the company's own annual report.
| Financial Year | Revenue | Net Profit | Operating Cash Flow | Free Cash Flow | CapEx | Cash | Total Debt | Short-Term Debt | Equity | Current Assets | Current Liabilities | Total Assets | Total Liabilities | Inventory | Dividends | Return on Equity (ROE) | Net Profit Margin | Debt-to-Equity | Current Ratio | Interest Coverage | Dividend Payout Ratio | Div yield | P/E Ratio | P/B Ratio |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | US$ 50.0b | US$ 9.2b | US$ 10.7b | US$ 9.3b | US$ -1.4b | US$ 9.6b | US$ 44.8b | US$ 1.0b | US$ 23.4b | US$ 29.8b | US$ 18.8b | US$ 88.8b | US$ 65.4b | US$ 2.7b | - | 39% | 18% | 1.9× | 1.6× | 7.9× | 55% | - | - | - |
| 2025 | US$ 48.2b | US$ 7.1b | US$ 14.2b | US$ 12.8b | US$ -1.3b | US$ 10.2b | US$ 47.1b | US$ 2.3b | US$ 18.5b | US$ 29.4b | US$ 23.4b | US$ 90.0b | US$ 71.5b | US$ 2.7b | US$ 248.0m | 38% | 15% | 2.6× | 1.3× | 5.9× | 72% | 5% | 15.0× | 5.7× |
| 2024 | US$ 48.3b | US$ -8.9b | US$ 15.2b | US$ 13.9b | US$ -1.2b | US$ 10.3b | US$ 51.2b | US$ 2.0b | US$ 16.3b | US$ 29.8b | US$ 23.8b | US$ 92.6b | US$ 76.2b | US$ 2.6b | US$ 240.0m | -55% | -19% | 3.1× | 1.3× | -3.3× | -54% | 5% | -11.8× | 6.5× |
| 2023 | US$ 45.0b | US$ 8.0b | US$ 13.9b | US$ 12.7b | US$ -1.2b | US$ 11.5b | US$ 41.5b | US$ 3.1b | US$ 29.4b | US$ 31.8b | US$ 22.3b | US$ 95.2b | US$ 65.7b | US$ 2.7b | US$ 228.0m | 27% | 18% | 1.4× | 1.4× | 8.2× | 59% | 5% | 11.2× | 3.1× |